|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
7 January 2013 |
|
Main ID: |
NCT01388062 |
|
Date of registration:
|
01/07/2011 |
|
Primary sponsor: |
|
|
Public title:
|
e- Ab Sensor - Based Real-time Diagnosis of Influenza Virus
|
|
Scientific title:
|
e- Ab Sensor - Based Real-time Diagnosis of Influenza Virus |
|
Date of first enrolment:
|
August 2010 |
|
Target sample size:
|
100 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT01388062 |
|
Study type:
|
Interventional |
|
Study design:
|
Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic
|
|
|
Countries of recruitment
|
|
Taiwan
| | | | | | | |
|
Contacts
|
|
Name:
|
Luan-Yin Chang, MD/PhD |
|
Address:
|
|
|
Telephone:
|
886-2-2312-3456 |
|
Email:
|
lychang@ntu.edu.tw |
|
Affiliation:
|
|
|
|
Name:
|
Shiming Lin, PhD |
|
Address:
|
|
|
Telephone:
|
886-2-23123456 |
|
Email:
|
til@ntu.edu.tw |
|
Affiliation:
|
|
|
|
Name:
|
Luan-Yin Chang, MD,PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
National Taiwan University Hospital |
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- A: The patients with confirmed or suspected infection.
- B: The patients without disease.
Exclusion Criteria:
- Patients will be excluded if they couldn't sign the consent.
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Influenza Caused by Unspecified Influenza Virus
|
|
Intervention(s)
|
|
Device: Electrosensing antibody probing system (e- Ab sensor)
|
|
Primary Outcome(s)
|
|
The performance of e- Ab sensor
[Time Frame: 1 Day]
|
|
Secondary ID(s)
|
|
201007054R
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|